Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, Astrazeneca Pharma India has informed that the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details.
The above information is a part of company’s filings submitted to BSE.